David Pharmaceuticals Changes Name to Saegis Pharmaceuticals; Company Targets Mild Cognitive Impairment, Other Problems of the Aging Mind.Business Editors & Health/Medical Writers HALF MOON BAY, Calif.--(BW HealthWire)--June 24, 2002 David Pharmaceuticals Inc., a privately held biopharmaceutical company focused on developing medicines for the problems of memory and cognition cognition Act or process of knowing. Cognition includes every mental process that may be described as an experience of knowing (including perceiving, recognizing, conceiving, and reasoning), as distinguished from an experience of feeling or of willing. associated with aging, today announced that it has changed its name to Saegis Pharmaceuticals Inc. "We are making rapid progress with our lead compounds while acquiring extensive clinical development expertise in this emerging field," said Rodney Rodney may refer to: Surnames
"Our new name, created by combining `sage' for wisdom and `aegis' for shield, articulates our vision to be at the forefront of the search for medicines that protect and enhance the function of the human mind." To date, Saegis Pharmaceuticals has in-licensed three novel agents from major pharmaceutical companies and research institutions. Each of these patented, orally active agents has demonstrated the ability to improve memory function in animal models while appearing to work through mechanisms unrelated to drugs typically used in the treatment of other cognitive disorders, such as Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Saegis Pharmaceuticals is currently moving two of these compounds through Phase II human clinical trials in the treatment of mild cognitive impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. . "With a number of important milestones ahead of them, this is the right time for Dr. Pearlman and his team to establish an identity for this company that better reflects its core focus and future potential," said Mark A. Cochran, Ph.D., managing director at NeuroVentures. "Saegis Pharmaceuticals is well positioned to take a leading role among a new generation of companies dedicated to conquering disorders of the brain and central nervous system." Mild cognitive impairment (or MCI (1) (Media Control Interface) A high-level programming interface from Microsoft and IBM for controlling multimedia devices. It provides commands and functions to open, play and close the device. (2) (Microwave Communications Inc. ) is one of several newly recognized, related conditions that affect an estimated 4.5 million to 8.7 million people over the age of 60. There are currently no safe and effective treatments to prevent or reverse this age-related decline in cognitive function cognitive function Neurology Any mental process that involves symbolic operations–eg, perception, memory, creation of imagery, and thinking; CFs encompasses awareness and capacity for judgment , often seen as a precursor precursor /pre·cur·sor/ (pre´kur-ser) something that precedes. In biological processes, a substance from which another, usually more active or mature, substance is formed. In clinical medicine, a sign or symptom that heralds another. to Alzheimer's disease. Founded in 1999, Saegis Pharmaceuticals (pronounced say-jis), formerly David Pharmaceuticals, is a pioneer in the clinical development of new medications for protecting and enhancing memory and mental function. Through licensing activity and development partnerships, Saegis Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the brain and central nervous system. For more information, visit www.saegispharma.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion